Circulating fibroblast growth factor 23 has a U-shaped association with atrial fibrillation prevalence

Circulation Journal

Volumn 79, Issue 8, 2015, Pages 1742-1748

  Miyamura, Masatoshi ^a   Fujita, Shu Ichi ^a   Morita, Hideaki ^a   Sakane, Kazushi ^a   Okamoto, Yusuke ^a   Sohmiya, Koichi ^a   Hoshiga, Masaaki ^a   Ishizaka, Nobukazu ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Atrial fibrillation; Chronic kidney disease; Fibroblast growth factor 23; Phosphate

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIFEDIOL; CREATININE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; VITAMIN D;

AGED; ARTICLE; ATRIAL FIBRILLATION; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE METABOLISM; PREVALENCE; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; COMPLICATION; JAPAN; KIDNEY DISEASES; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREVALENCE; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84937961525     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0413     Document Type: Article

References (44)

1. Jover E, Marin F, Roldan V, Montoro-Garcia S, Valdes M, Lip GY. Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Ann Med 2013; 45: 274-290.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
3. Rosiak M, Dziuba M, Chudzik M, Cygankiewicz I, Bartczak K, Drozdz J, et al. Risk factors for atrial fibrillation: Not always severe heart disease, not always so ‘lonely’. Cardiol J 2010; 17: 437-442.
4. Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008; 72: 909-913.
5. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011; 22: 349-357.
6. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 2946-2953.
7. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 173-181.
8. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013; 127: 569-574.
9. Razzaque MS. The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619.
10. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resemfunction H. Pathophysiological roles of FGF signaling in the heart. Front Physiol 2013; 4: 247.
11. Ali FN, Falkner B, Gidding SS, Price HE, Keith SW, Langman CB. Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. J Pediatr 2014; 165: 738-743.e731, doi:710.1016/j.jpeds.2014.1006.1027.
12. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
13. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304: E863-E873.
14. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012; 21: 369-375.
15. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, et al. The phosphatonin fibroblast growth factor 23 links calciumphosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688-2696.
16. Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014; 130: 298-307.
17. Alonso A, Misialek JR, Eckfeldt JH, Selvin E, Coresh J, Chen LY, et al. Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities study. J Am Heart Assoc 2014; 3: e001082, doi:001010.001161/JAHA.001114.001082.
18. Inoue H, Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. Circ J 2014; 78: 2388-2393.
19. Tomita T, Hata T, Takeuchi T, Oguchi Y, Okada A, Aizawa K, et al. High concentrations of omega-3 fatty acids are associated with the development of atrial fibrillation in the Japanese population. Heart Vessels 2013; 28: 497-504.
20. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
21. Fujita S, Okamoto Y, Shibata K, Morita H, Ito T, Sohmiya K, et al. Serum uric acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients. PLoS One 2013; 8: e82735, doi:10.1371/journal.pone.0082735.
22. Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, et al. Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One 2013; 8: e73184, doi:10.1371/journal.pone.0073184.
23. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146: 4647-4656.
24. Ratanapo S, Kittanamongkolchai W, Srivali N, Ahmed S, Cheungpasitporn W, Chongnarungsin D. The role of fibroblast growth factor-23 in left atrial volume. Am Heart J 2013; 165: e21, doi:10.1016/j.ahj.2013.1002.1022.
25. Sciacqua A, Perticone M, Tripepi G, Miceli S, Tassone EJ, Grillo N, et al. Renal disease and left atrial remodeling predict atrial fibrillation in patients with cardiovascular risk factors. Int J Cardiol 2014; 175: 90-95.
26. Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: 902-909.e2, doi:10.1016/j.ahj.2012.09.018.
27. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, et al. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol 2010; 163: 825-831.
28. Tamez H, Andress D, Solomon SD, Thadhani R. Reply to “The role of fibroblast growth factor-23 in left atrial volume”. Am Heart J 2013; 165: e23, doi:10.1016/j.ahj.2013.1002.1023.
29. Lopez FL, Agarwal SK, Grams ME, Loehr LR, Soliman EZ, Lutsey PL, et al. Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study). Am J Cardiol 2013; 111: 857-862.
30. Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hypertens Res 2007; 30: 535-540.
31. Negishi K, Kobayashi M, Ochiai I, Yamazaki Y, Hasegawa H, Yamashita T, et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ J 2010; 74: 2734-2740.
32. Rienstra M, Lubitz SA, Zhang ML, Cooper RR, Ellinor PT. Elevation of parathyroid hormone levels in atrial fibrillation. J Am Coll Cardiol 2011; 57: 2542-2543.
33. Loncar G, Bozic B, Dimkovic S, Prodanovic N, Radojicic Z, Cvorovic V, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest 2011; 34: e78-e85, doi:10.1007/BF03347080.
34. Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8: e60658, doi:10.1371/journal.pone.0060658.
35. Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014; 307: E426-E436.
36. Kalyanasundaram A, Fedorov VV. Fibroblast growth factor 23: A novel key to find hidden substrates of atrial fibrillation? Circulation 2014; 130: 295-297.
37. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819.
38. Raviele A, Ronco F. Endothelial dysfunction and atrial fibrillation: What is the relationship? J Cardiovasc Electrophysiol 2011; 22: 383-384.
39. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J 2009; 158: 629-636.
40. Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010; 28: 1738-1744.
41. Deo R, Katz R, Kestenbaum B, Fried L, Sarnak MJ, Psaty BM, et al. Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail 2010; 16: 55-60.
42. Sano F, Ohira T, Kitamura A, Imano H, Cui R, Kiyama M, et al. Heavy alcohol consumption and risk of atrial fibrillation: The Circulatory Risk in Communities Study (CIRCS). Circ J 2014; 78: 955-961.
43. Misialek JR, Lopez FL, Lutsey PL, Huxley RR, Peacock JM, Chen LY, et al. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans: Atherosclerosis Risk in Communities (ARIC) study. Circ J 2013; 77: 323-329.
44. JCS Joint Working Group. Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011): Digest version. Circ J 2013; 77: 249-274.